An observational study in Histiocytosis, sponsored by Tampere University Hospital. Enrolling by invitation at 1 site in Finland. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Tampere University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to describe a new disease condition of histiocytosis related to injecting drug use, its preconditions, symptoms, signs, findings, and prognosis in a detailed and systematic patient series in one referral center. The main question[s] it aims to answer are:
The patient history will be collected from the data produced by follow-up of cases followed up in a single center. A subgroup of participants will be given an opportunity to sign informed consent to give access to/donate blood and tissue samples to search for techniques to prove polyvinylpyrrolidone storage within histiocytes, and to search for transcriptomics signal(s) in histiocytes.
Researchers will compare blood and tissue samples from the biobank as controls.
Comprehensive patient data (disease history, findings, complications, laboratory findings, histopathology, and imaging) will be obtained from patient records of a single university hospital. Coded histiocytosis-positive tissue samples will be compared to biobank samples from corresponding tissues from healthy and other histiocytosis tissue samples to show polyvinylpyrrolidone storage with novel methodologies.
In addition, if a study participant who is followed up clinically, signs informed consent, monocytes are separated from a blood sample, differentiated to macrophages, and exposed to polyvinylpyrrolidone. Various novel methods will be utilized to explore polyvinylpyrrolidone within histiocytes.
25 studies on the registry are indexed under Histiocytosis; 8 are open to participants now.
Browse Histiocytosis studies →Tampere University Hospital is the lead sponsor of 212 studies on the registry; 56 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients admitting to intravenous use of dissolved tablets (indicated for oral use) containing polyvinylpyrrolidone (PVP30) and positive tissue sample in any tissue biopsy compatible with features of histiocytosis caused by PVP30
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No intervention
Diagnostic Test: Chitotriosidase · Diagnostic Test: Mass spectrometry · Diagnostic Test: scanning electron microscope with energy-dispersive X-ray spectroscopy · Diagnostic Test: Fluorescence microscopy · Diagnostic Test: Transcriptomics
The amount of patients with increased chitotriosidase, and the extent of elevation of chitotriosidase
to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
To describe pathologic signals of polyvinylpyrrolidone-exposed in vitro histiocytes of injecting drug users compared to control samples
Frequency of disease manifestations
To describe phenotype
Time frame: 10 years
Frequency of elevated chitotriosidase activity
Is chitotriosidase activity associated with polyvinylpyrrolidone histiocytosis
Time frame: 10 years
Mortality
Mortality
Time frame: 10 years
Microscopic fluorescence positive tissue
Search for specific polyvinylpyrrolidone fluorescence signal
Time frame: 10 years
Scanning electron microscope with energy-dispersive X-ray spectroscopy
search for specific polyvinylpyrrolidone signal within cells
Time frame: 10 years
Pyrolysis mass spectrometry
search for specific polyvinylpyrrolidone signal within cells
Time frame: 10 years
Transcriptomics analysis
Search for immunologic pathway-specific abnormalities to guide treatment in cases compared with controls
Time frame: 10 years
Plan to share: No — Study data can only be acquired by proper inquiry to the national authority Findata by law
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Dec 2030, 91 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.